Open models play a crucial role in fostering a diverse and innovative AI ecosystem. But their irrevocable accessibility also presents challenges for preventing downstream misuse—and that has caught the government’s attention....more
9/6/2024
/ Artificial Intelligence ,
Best Practices ,
Biden Administration ,
Executive Orders ,
Governor Newsom ,
NIST ,
NTIA ,
Pending Legislation ,
Proposed Legislation ,
Public Comment ,
Regulatory Agenda ,
Regulatory Oversight ,
U.S. Commerce Department
AI is shaving years off the drug-discovery process. But it’s not just leaving other research modalities in the dust—the law itself is struggling to keep up, especially when it comes to patenting AI-aided drug discovery....more
6/14/2024
/ Artificial Intelligence ,
Inventors ,
Life Sciences ,
Machine Learning ,
Patents ,
Pharmaceutical Industry ,
Research and Development ,
Risk Assessment ,
Risk Management ,
Startups ,
Strategic Planning ,
USPTO
AI is vaulting drug discovery forward leaps and bounds—and now regulators are beginning to catch up, with the United States Patent and Trademark Office recently issuing new guidelines on the patentability of AI-assisted...more